MX367082B - Anticuerpos anti toxina alfa de s. aureus (anti-ta) y sus usos. - Google Patents

Anticuerpos anti toxina alfa de s. aureus (anti-ta) y sus usos.

Info

Publication number
MX367082B
MX367082B MX2015005481A MX2015005481A MX367082B MX 367082 B MX367082 B MX 367082B MX 2015005481 A MX2015005481 A MX 2015005481A MX 2015005481 A MX2015005481 A MX 2015005481A MX 367082 B MX367082 B MX 367082B
Authority
MX
Mexico
Prior art keywords
aureus
methods
treating
preventing
reducing
Prior art date
Application number
MX2015005481A
Other languages
English (en)
Other versions
MX2015005481A (es
Inventor
Sellman Bret
Huang Lei
Tkaczyk Christine
Hamilton Melissa
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2015005481A publication Critical patent/MX2015005481A/es
Publication of MX367082B publication Critical patent/MX367082B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/02Peptides of undefined number of amino acids; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/085Staphylococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a métodos para prevenir y/o tratar la bacteriemia y la septicemia asociadas con S. aureus, y métodos para prevenir y/o tratar la neumonía asociada con S. aureus en pacientes inmunodeprimidos utilizando anticuerpos contra la toxina alfa de S. aureus (anti-TA). También se proporcionan métodos para reducir la carga bacteriana de S. aureus en el torrente sanguíneo o el corazón de un sujeto que es un mamífero, que comprenden administrar al sujeto una cantidad efectiva de un anticuerpo contra la toxina alfa de S. aureus (anti-TA) aislado o un fragmento de unión al antígeno de este. También se proporcionan métodos para reducir la aglutinación bacteriana y/o formación de lesiones tromboembólicas en un sujeto que es un mamífero, que comprenden administrar al sujeto una cantidad efectiva de un anticuerpo contra la toxina alfa de S. aureus (anti-TA) aislado o un fragmento de unión al antígeno de este. También se proporcionan métodos para prevenir o reducir la gravedad de la neumonía asociada con S. aureus en un sujeto que es un mamífero inmunodeprimido.
MX2015005481A 2012-11-06 2013-11-05 Anticuerpos anti toxina alfa de s. aureus (anti-ta) y sus usos. MX367082B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261723128P 2012-11-06 2012-11-06
PCT/US2013/068385 WO2014074470A1 (en) 2012-11-06 2013-11-05 Methods of treating s. aureus-associated diseases

Publications (2)

Publication Number Publication Date
MX2015005481A MX2015005481A (es) 2016-01-14
MX367082B true MX367082B (es) 2019-08-05

Family

ID=50685101

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005481A MX367082B (es) 2012-11-06 2013-11-05 Anticuerpos anti toxina alfa de s. aureus (anti-ta) y sus usos.

Country Status (14)

Country Link
US (3) US9845348B2 (es)
EP (1) EP2928490B1 (es)
JP (2) JP6506172B2 (es)
KR (3) KR102272744B1 (es)
CN (2) CN112316135A (es)
AU (2) AU2013341421A1 (es)
BR (1) BR112015010126B1 (es)
CA (1) CA2890385C (es)
ES (1) ES2912267T3 (es)
HK (1) HK1215173A1 (es)
MX (1) MX367082B (es)
RU (1) RU2661406C2 (es)
SG (2) SG11201503231YA (es)
WO (1) WO2014074470A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102111171B1 (ko) 2011-06-10 2020-05-14 메디뮨 엘엘씨 항슈도모나스 psl 결합 분자 및 그의 용도
KR102184343B1 (ko) 2011-11-07 2020-11-30 메디뮨 엘엘씨 항슈도모나스 psl 및 pcrv 결합 분자를 이용한 병용 요법
PL2917360T3 (pl) 2012-11-06 2020-06-29 Medimmune, Llc Przeciwciała dla determinant powierzchniowych S. aureus
KR102272744B1 (ko) * 2012-11-06 2021-07-06 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
TW202311284A (zh) 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素a毒素之人類抗體
WO2020023644A2 (en) 2018-07-24 2020-01-30 Medimmune, Llc Antibody directed against s. aureus clumping factor a (clfa)
CA3115633A1 (en) 2018-10-09 2020-04-16 Medimmune, Llc Combinations of anti-staphylococcus aureus antibodies
WO2020076790A1 (en) 2018-10-09 2020-04-16 Medimmune, Llc Antibodies directed against staphylococcus aureus leukotoxins
CN112538112B (zh) * 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ574057A (en) * 2006-06-12 2012-01-12 Glaxosmithkline Biolog Sa Staphylococcal antigen composition comprising an isolated S. aureus type 5 antigen; an isolated S. aureus type 8 antigen; an isolated S. aureus 336 antigen; an isolated S. aureus alpha-toxin antigen; and an isolated Staphylococcal leukocidin antigen
CA2697538C (en) * 2007-08-31 2019-02-12 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
CA2768242C (en) * 2009-07-16 2015-11-17 Georgia Health Sciences University Research Institute, Inc. Porous-wall hollow glass microspheres as carriers for biomolecules
EP2284193A1 (en) * 2009-08-10 2011-02-16 Kenta Biotech AG Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation
WO2012109167A1 (en) * 2011-02-08 2012-08-16 Integrated Biotherapeutics, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
EP2673373B3 (en) 2011-02-08 2021-06-02 MedImmune, LLC Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
PL2917360T3 (pl) 2012-11-06 2020-06-29 Medimmune, Llc Przeciwciała dla determinant powierzchniowych S. aureus
KR102272744B1 (ko) * 2012-11-06 2021-07-06 메디뮨 엘엘씨 에스.아우레우스 연관 질병의 치료 방법
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
WO2017075188A2 (en) 2015-10-30 2017-05-04 Medimmune, Llc Methods of using anti-alpha toxin antibody

Also Published As

Publication number Publication date
CA2890385C (en) 2022-07-12
US10759849B2 (en) 2020-09-01
AU2018236849B2 (en) 2020-05-21
KR20150092738A (ko) 2015-08-13
BR112015010126A2 (es) 2017-08-22
US20190002540A1 (en) 2019-01-03
US20200109191A1 (en) 2020-04-09
JP2019142888A (ja) 2019-08-29
MX2015005481A (es) 2016-01-14
RU2661406C2 (ru) 2018-07-16
US10457724B2 (en) 2019-10-29
RU2015121617A (ru) 2016-12-27
HK1215173A1 (zh) 2016-08-19
JP6926138B2 (ja) 2021-08-25
US20160257733A1 (en) 2016-09-08
BR112015010126B1 (pt) 2022-11-01
AU2018236849A1 (en) 2018-10-18
SG11201503231YA (en) 2015-05-28
US9845348B2 (en) 2017-12-19
ES2912267T3 (es) 2022-05-25
EP2928490A4 (en) 2016-11-02
EP2928490A1 (en) 2015-10-14
CA2890385A1 (en) 2014-05-15
CN104780934A (zh) 2015-07-15
JP6506172B2 (ja) 2019-04-24
EP2928490B1 (en) 2022-03-30
AU2013341421A1 (en) 2015-06-04
JP2015536951A (ja) 2015-12-24
SG10201703677VA (en) 2017-06-29
WO2014074470A1 (en) 2014-05-15
KR20210083389A (ko) 2021-07-06
KR102272744B1 (ko) 2021-07-06
CN112316135A (zh) 2021-02-05
KR20200102533A (ko) 2020-08-31

Similar Documents

Publication Publication Date Title
MX2015005481A (es) Metodos para tratar enfermedades asociadas con s. aureus.
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
NZ709997A (en) Methods for treating conditions associated with masp-2 dependent complement activation
NZ630363A (en) Anti-kit antibodies and uses thereof
WO2013119716A8 (en) Compositions and methods for using csf1r inhibitors
MX2015006681A (es) Formulaciones de vancomicina estabilizadas.
MX2020009700A (es) Anticuerpos que se unen especificamente a la toxina alfa de staphylococcus aureus y metodos de uso.
MX2018010776A (es) Moleculas de union de antigeno multiespecificas y usos de las mismas.
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
EA201692042A1 (ru) Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
BR112015010125A2 (pt) Anticorpo isolado ou seu fragmento de ligação, composição, ácido nucleico isolado, métodos de determinação da presença de s. aureus em uma amostra de teste, de tratamento de uma infecção por s. aureus em um paciente, de prevenção ou redução da gravidade de sepsia associada a s. aureus em um paciente, de atraso do início de sepsia associada a infecção por s. aureus em um paciente, de prevenção do início de sepsia associada a infecção por s. aureus em um paciente, de redução de carga bacteriana de s. aureus na corrente sanguínea ou coração em um paciente, e de redução da aglutinação bacteriana de s. aureus e/ou formação de lesões tromboembólicas em um paciente
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
MX2013012393A (es) Anticuerpos anti-receptor tipo proteina-tirosina-fosfatasa sigma humano.
BR112016002401A2 (pt) métodos para reduzir as taxas de exacerbação de asma usando benralizumab
MX2014000363A (es) Anticuerpos monoclonales inhibidores anti-factor xii-xiia.
MX2015007147A (es) Metodo de reduccion de placas amiloides de cerebro que usan anticuerpos anti-ab.
SG10201804809RA (en) Clostridium difficile antibodies
TW201613575A (en) Treatment of polybacterial infections
NZ629828A (en) Methods for the treatment of b cell-mediated inflammatory diseases
AU2018256482A1 (en) Antibodies Against Clostridium Difficile
GB201109238D0 (en) Antibodies
EP3492101A3 (en) Agents for influenza neutralization
MX357708B (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
WO2020023644A3 (en) Antibody directed against s. aureus clumping factor a (clfa)

Legal Events

Date Code Title Description
FG Grant or registration